Sugi Predict

Sugi Predict / Compounds / SCHEMBL508571

SCHEMBL508571

SCHEMBL508571

CCOC(=O)c1cc(-c2cccs2)on1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.61
▸ RAB9A P51151 6/20 0.60
▸ SMN1; SMN2 Q16637 5/20 0.60
▸ NPC1 O15118 4/20 0.60
▸ KDM4E B2RXH2 6/20 0.59
▸ MAPT P10636 5/20 0.59
▸ TP53 P04637 3/20 0.59
▸ THRB P10828 2/20 0.59
▸ HPGD P15428 3/20 0.58
▸ LMNA P02545 3/20 0.58
▸ HSD17B10 Q99714 1/20 0.57
▸ ALDH1A1 P00352 5/20 0.56
▸ MEN1 O00255 4/20 0.56
▸ HTT P42858 1/20 0.56
▸ GAA P10253 1/20 0.56
▸ CASP1 P29466 1/20 0.56
▸ POLB P06746 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.53
▸ ESR1 P03372 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20507129 0.84 KMT2A (0.71) KMT2ARAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL4280282 0.80 RAB9A (0.69) KMT2ARAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL9911642 0.80 RAB9A (0.67) KMT2ARAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL27176304 0.80 MAPT (0.48) KMT2AMAPTTHRBHPGDLMNA
SCHEMBL15001259 0.79 RAB9A (0.65) KMT2ARAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL8209372 0.79 KMT2A (0.62) KMT2ARAB9ANPC1KDM4EMAPT
SCHEMBL15931869 0.78 NPC1 (0.50) KMT2ARAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL768649 0.78 ACR (0.63) KMT2ARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL21523771 0.78 ALDH1A1 (0.47) KMT2ARAB9ANPC1KDM4EMAPT
SCHEMBL21523702 0.78 MAPT (0.46) KDM4EMAPTLMNAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180273906-A1 MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS IPS HEART 2018-09-27 — — US claimed
US-20220117945-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2022-04-21 — — US disclosed
US-20220117945-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2022-04-21 — — US disclosed
US-20210355115-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2021-11-18 — — US disclosed
US-20210355115-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2021-11-18 — — US disclosed
EP-3853212-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF Novartis AG (CH) 2021-07-28 — — EP disclosed
CN-113056455-A Isoxazole carboxamide compounds and uses thereof 诺华股份有限公司 2021-06-29 — — CN disclosed
US-20210054344-A1 CPC EXOSOMES MIRNA373 COMBINATION THERAPIES IPS HEART 2021-02-25 — — US disclosed
WO-2020058913-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2020-03-26 — — WO disclosed
EP-3601276-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF Novartis AG (CH) 2020-02-05 — — EP disclosed
US-20090036451-A1 Chemical inducers of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2009-02-05 — — US disclosed
US-20090036451-A1 Chemical inducers of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2009-02-05 — — US disclosed
WO-2008046072-A2 CHEMICAL INDUCERS OF NEUROGENESIS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2008-04-17 — — WO disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 — — EP disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 — — WO disclosed
EP-0986562-B1 SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS MERCK SHARP & DOHME (GB) 2002-08-07 — — EP disclosed
US-6310203-B1 Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands MERCK SHARPE & DOHME LIMITED (GB) 2001-10-30 — — US disclosed
US-6200975-B1 FOR COGNITION ENHANCEMENT THERAPY MERCK SHARP & DOHME LIMITED (GB) 2001-03-13 — — US disclosed
EP-0986562-A1 SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS MERCK SHARP & DOHME LTD. (GB) 2000-03-22 — — EP disclosed
WO-1998050385-A1 SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1998-11-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180273906-A1 MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS EXOSC9, EXOSC5, EXOSC4 KMT2A 2981/4885RAB9A 334/4885SMN1; SMN2 14/4885
US-20210355115-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF SLC26A4, ALDH5A1, SLC8B1 KMT2A 3484/4885RAB9A 1326/4885SMN1; SMN2 743/4885
US-20210054344-A1 CPC EXOSOMES MIRNA373 COMBINATION THERAPIES EXOSC5, UTRN, EXOSC4 KMT2A 2437/4885RAB9A 2257/4885SMN1; SMN2 13/4885
US-20090036451-A1 Chemical inducers of neurogenesis DCX, NES, GAP43 KMT2A 1862/4885RAB9A 2878/4885SMN1; SMN2 929/4885
US-20220117945-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF SLC26A4, SLC26A3, ALDH5A1 KMT2A 3481/4885RAB9A 1566/4885SMN1; SMN2 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.